KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Research & Development: 2018-2024

Historic Research & Development for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $52.0 million.

  • Castle Biosciences' Research & Development rose 5.17% to $13.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.1 million, marking a year-over-year decrease of 5.92%. This contributed to the annual value of $52.0 million for FY2024, which is 2.94% down from last year.
  • As of FY2024, Castle Biosciences' Research & Development stood at $52.0 million, which was down 2.94% from $53.6 million recorded in FY2023.
  • Castle Biosciences' Research & Development's 5-year high stood at $53.6 million during FY2023, with a 5-year trough of $13.3 million in FY2020.
  • Moreover, its 3-year median value for Research & Development was $52.0 million (2024), whereas its average is $50.2 million.
  • Its Research & Development has fluctuated over the past 5 years, first spiked by 123.64% in 2021, then decreased by 2.94% in 2024.
  • Yearly analysis of 5 years shows Castle Biosciences' Research & Development stood at $13.3 million in 2020, then surged by 123.64% to $29.6 million in 2021, then spiked by 51.46% to $44.9 million in 2022, then rose by 19.41% to $53.6 million in 2023, then decreased by 2.94% to $52.0 million in 2024.